Venenum Biodesign

Venenum Biodesign is a private U.S. drug discovery company and CRO focused on discovering new drug targets and advancing small-molecule medicines for unmet medical needs. The company is part of Genesis Biotechnology Group and operates within the Genesis Drug Discovery & Development network. Its internal pipeline appears centered on immuno-oncology and metabolic disease, with disclosed programs including STING agonists for cancer and MGAT2 inhibitors for obesity and fatty liver disease. In parallel, Venenum offers discovery services spanning assay development, ultra-high-throughput screening, medicinal chemistry, structural biology, compound profiling, and hit-to-lead/lead-optimization work. The company highlights its proprietary ECLiPS compound collection and screening approach as the core of both its partnered services and internal pipeline generation.